Keyphrases
Adjuvant Chemotherapy
17%
Advanced Solid Tumors
50%
Antitumor Activity
24%
Ashkenazi
14%
Bevacizumab
15%
BRCA mutation
16%
Cetuximab
13%
Chemotherapy
59%
Clinical Outcomes
19%
Colon Cancer
17%
Colorectal Cancer
76%
Colorectal Cancer Patients
18%
Colorectal Liver Metastases
22%
Confidence Interval
16%
First-in-class
18%
FOLFIRINOX
16%
Gastric Cancer
24%
Germline mutation
14%
Immune Checkpoint Inhibitors
16%
Immunoglobulin-like Transcript 4
16%
Israeli
29%
Jewish
13%
Liver
18%
Metastatic Colorectal Cancer (mCRC)
76%
Monotherapy
28%
Neoadjuvant
22%
Neoadjuvant Chemotherapy
14%
Nonfunctional Pancreatic Neuroendocrine Tumor
16%
Objective Response Rate
26%
Overall Survival
40%
Oxaliplatin
20%
Paclitaxel
16%
Pancreatic Cancer
33%
Pancreatic Ductal Adenocarcinoma
15%
Pancreatic Neuroendocrine Tumors (pNETs)
17%
PD-1 Resistance
16%
Pembrolizumab
100%
Phase II Trial
23%
Previously Treated
31%
Primary Tumor
17%
Programmed Death-ligand 1 (PD-L1)
32%
Progression-free Survival
17%
Ramucirumab
16%
Resection
18%
Resistance Mechanisms
16%
Retrospective Analysis
15%
Selective Internal Radiation Therapy
16%
Specific Antibodies
16%
Treatment-related Adverse Events
21%
Tumor
17%
Pharmacology, Toxicology and Pharmaceutical Science
2,5-Dimethoxy-4-iodoamphetamine
10%
Adenocarcinoma
20%
Adverse Event
40%
Antibodies
16%
Antitumor Activity
20%
Bispecific Antibody
10%
Cetuximab
14%
Chemokine Receptor
10%
Chemoradiation Therapy
10%
Chemotherapy
59%
Chemotherapy Regimens
9%
Colon Cancer
21%
Colorectal Cancer
36%
Combination Therapy
15%
Digestive System Cancer
14%
Disease
44%
Disease Exacerbation
9%
Fluorouracil
19%
Folinic Acid
15%
Head and Neck Squamous Cell Carcinoma
10%
Immune Checkpoint Inhibitor
8%
Immunoglobulin Antibody
10%
Immunotherapy
9%
Liver Metastasis
11%
Malignant Neoplasm
54%
Metastatic Colorectal Cancer
60%
Monoclonal Antibody
21%
Monotherapy
28%
Navarixin
10%
Neoplasm
47%
Overall Survival
41%
Oxaliplatin
15%
Paclitaxel
16%
Pancreas Adenocarcinoma
13%
Pancreas Cancer
36%
Pectin
10%
Pembrolizumab
88%
Pharmacokinetics
18%
Placebo
13%
Programmed Cell Death
10%
Programmed Death 1 Ligand 1
9%
Progression Free Survival
30%
Prostate Cancer
10%
Ramucirumab
16%
Rectum Cancer
11%
Recurrent Disease
19%
Salicylate Sodium
10%
Solid Malignant Neoplasm
65%
Stomach Cancer
30%
Tolerability
9%
Medicine and Dentistry
4 Iodo 2,5 Dimethoxyamphetamine
16%
Adenocarcinoma
12%
Adjuvant Chemotherapy
17%
Adverse Event
22%
Antibodies
10%
Antineoplastic Activity
12%
Biological Marker
13%
BRCA Mutation
16%
Breast Cancer
11%
Chemoradiotherapy
20%
Clinical Trial
12%
Colon Cancer
18%
Colonoscopy
13%
Colorectal Cancer
53%
Colorectal Liver Metastasis
11%
Disease
27%
Family History
11%
FOLFOX
12%
Gastroesophageal Junction
20%
Hepatectomy
12%
Hepatocellular Carcinoma
11%
Ileostomy
10%
Immune Checkpoint Inhibitor
14%
Immunotherapy
11%
Intention-to-Treat Analysis
13%
Intraperitoneal Chemotherapy
10%
Liver Metastasis
14%
Malignant Neoplasm
54%
Metastatic Carcinoma
26%
Metastatic Colorectal Cancer
39%
Monotherapy
12%
Neoadjuvant Chemotherapy
14%
Neoadjuvant Therapy
11%
Neoplasm
42%
Overall Survival
53%
Oxaliplatin
12%
Pancreas Cancer
42%
Pancreas Islet Cell Tumor
25%
Pembrolizumab
57%
Peritoneum Metastasis
10%
Placebo
17%
Primary Tumor
17%
Progression Free Survival
28%
Radiation Therapy
16%
Rectum Cancer
38%
Recurrent Disease
26%
Selective Internal Radiation Therapy
10%
Solid Malignant Neoplasm
10%
Stomach Cancer
22%
Surgery
23%
